Indian pharmaceutical firm Caplin Point reports a 20% rise in first-quarter revenue, driven by a tripling of its US injectable business and strategic expansion plans amid a strong balance sheet.
Caplin Point Laboratories said its first-quarter revenue rose 20% year on year, helped by broad-based growth across its US and emerging-markets businesses. The company’s US injectable operation was the standout, with revenue tripling to 43.1 crore rupees, while the wider US market grew 26% and emerging markets advanced 18%, according to the earnings-call summary.
The stronger topline fed through to profitability. EBITDA margin improved to 38.4% from 37.7% a year earlier, as operating expenses fell as a share of revenue. The company also highlighted a strong balance sheet, with 1,500 crore rupees in free cash and 2,875 crore rupees in total liquid assets, and said it had no external bank debt. At the same time, cash flow from operations eased to 98 crore rupees after the company deliberately lifted inventories to guard against supply-chain disruption.
Not all parts of the business moved in the same direction. Rest-of-world profitability slipped to about 33% from 37.5% a year earlier, which management attributed to higher marketing spending in newer markets and other normal business swings rather than a structural decline. Receivables also increased, largely because of government supplies that are expected to be collected later in the year.
The company is still investing heavily to support future growth. Management said it is adding injectable lines, expanding oncology capacity, building out API capabilities and evaluating a distribution acquisition in Mexico. ICICI Direct said Caplin is planning to launch 15 new products in the US and is backing that ambition with about 1,000 crore rupees of expansion spending. In the earnings call, management said current capacity is tight, with the company booked out until February, and outlined a phased ramp-up of new lines through 2029 and beyond. It also said Amaris Clinical will mainly support internal bioequivalence work for now, cutting study costs by about half versus outside centres. On tariffs and possible US policy changes, the company struck a wait-and-see tone, saying it would reassess if the environment shifts.
Disclaimer: This article is intended to inform and educate, not to recommend or endorse any financial product, investment or strategy. Please consider your own financial circumstances and seek professional advice where appropriate before making financial decisions.
